Michelle Vanhove
Family · Sioux Falls, SDNPI 1679837413
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,801 of the $6,900 with a category attached, or 84.1%. 19 manufacturers reported payments, led by Abbott at 52.4% of the total. Among family clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $29.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Abiomed$606
- Cvrx, Inc.$528
- E.r. Squibb & Sons, L.L.C.$514
- Actelion Pharmaceuticals US, Inc.$414
- Johnson & Johnson$349
- plus $877 from 13 others
What the payments were for
- Travel & lodging$1,09816%
- Food & beverage$5,80184%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 70 | $3,612 |
| Abiomed | 8 | $606 |
| Cvrx, Inc. | 5 | $528 |
| E.r. Squibb & Sons, L.L.C. | 43 | $514 |
| Actelion Pharmaceuticals US, Inc. | 13 | $414 |
| Johnson & Johnson | 37 | $349 |
| AstraZeneca | 14 | $208 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 11 | $104 |
| Amarin Pharma, Inc. | 8 | $101 |
| Novartis | 6 | $95 |
| United Therapeutics Corporation | 4 | $82 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Merck | 2 | $46 |
| Pfizer | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Cardiac Dimensions, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,900 in reported general payments places this provider in the 95th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 86 | $1,088,243 |
| EntrestoSacubitril/Valsartan | 362 | $342,491 |
| VyndaqelTafamidis Meglumine | 11 | $239,514 |
| FarxigaDapagliflozin Propanediol | 201 | $186,852 |
| EliquisApixaban | 88 | $88,235 |
| JardianceEmpagliflozin | 58 | $42,316 |
| XareltoRivaroxaban | 22 | $26,667 |
| Tadalafil | 36 | $23,461 |
| Torsemide | 293 | $11,186 |
| Sildenafil Citrate | 20 | $9,200 |
| Potassium Chloride | 239 | $9,089 |
| Metoprolol Succinate | 468 | $7,666 |
| Furosemide | 566 | $2,645 |
| Spironolactone | 382 | $2,297 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 45 | $1,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $414 | $1,088,24386 claims |
| NovartisEntresto | $95 | $342,491362 claims |
| PfizerVyndaqel, Eliquis | $42 | $327,74999 claims |
| AstraZenecaFarxiga | $208 | $186,852201 claims |
| Boehringer IngelheimJardiance | $33 | $42,31658 claims |
| Johnson & JohnsonXarelto | $349 | $26,66722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 588 family providers in South Dakota.
Other family in Sioux Falls
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
- Megan MoedingSioux Falls$5K
- Kari WestenkirchnerSioux Falls$4K
- Brooke MunkSioux Falls$4K
- Rebekka KlemmeSioux Falls$4K
- Jordyn HoferSioux Falls$3K
- Jennifer RedmondSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.